Zoetis Faces Securities Class Action Over Alleged Misleading Sales Data

The litigation, titled City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., claims the animal health giant misrepresented the trajectory of key revenue drivers. According to the complaint, Zoetis failed to disclose that demand for its canine pain treatment, Librela, was flagging after FDA safety warnings surfaced regarding neurological complications. Furthermore, the filing alleges that Simparica Trio and core dermatological products like Apoquel and Cytopoint were hemorrhaging market share to lower-priced competitors throughout the class period.

The volatility culminated on May 7, 2026, when Zoetis reported first-quarter financial results that exposed significant declines in its companion animal segment. The market reaction was immediate, with the company's stock price dropping 21.5% in response to the disclosure. Investors now have until July 27, 2026, to file for lead plaintiff status in the ongoing case. The law firm Kessler Topaz Meltzer & Check, LLP is currently offering case evaluations for affected shareholders interested in pursuing recovery options.